Portfolio company
ArkVax
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
ArkVax develops low-cost recombinant glycoconjugate vaccines for the livestock industry to protect animals from bacterial diseases and combat antimicrobial resistance.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ArkeaBio
This company develops a vaccine to reduce methane emissions from cattle for livestock farmers and global food producers.
ViroVet
This company develops vaccines and antiviral drugs for livestock to control respiratory diseases and other viral infections in cattle, swine, sheep and goats.
FeedVax
This company develops oral vaccines for the aquaculture industry to reduce fish stress and antibiotic use for producers.
The Vaccine Group
The company develops recombinant viral-vector vaccines and biotherapeutics for livestock and companion animals to control infectious and chronic diseases.
PhageLab
PhageLab develops bacteriophage treatments to control bacterial pathogens in livestock and poultry production, reducing the industry's reliance on antibiotics.
Baseimmune
The company develops AI-designed vaccines and antigens for pharmaceutical partners and biotech researchers to treat infectious diseases and chronic conditions in humans and animals.
Animab
Animab develops oral monoclonal antibody products for livestock farmers to control gastrointestinal pathogens and improve animal health without using antibiotics.
Resilient Biotics
This company develops microbiome-derived live biotherapeutics to prevent and treat respiratory diseases in livestock and humans.
